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Abstract
Introduction: Daily or serial evaluation of multiple organ dysfunction syndrome (MODS) scores may provide useful
information. We aimed to validate the daily (d) PELOD-2 score using the set of seven days proposed with the
previous version of the score.
Methods: In all consecutive patients admitted to nine pediatric intensive care units (PICUs) we prospectively
measured the dPELOD-2 score at day 1, 2, 5, 8, 12, 16, and 18. PICU mortality was used as the outcome dependent
variable. The discriminant power of the dPELOD-2 scores was estimated using the area under the ROC curve and
the calibration using the Hosmer-Lemeshow chi-square test. We used a logistic regression to investigate the
relationship between the dPELOD-2 scores and outcome, and between the change in PELOD-2 score from day1
and outcome.
Results: We included 3669 patients (median age 15.5 months, mortality rate 6.1 %, median length of PICU stay 3
days). Median dPELOD-2 scores were significantly higher in nonsurvivors than in survivors (p < 0.0001). The
dPELOD-2 score was available at least at day 2 in 2057 patients: among the 796 patients without MODS on day1,
186 (23.3 %) acquired the syndrome during their PICU stay (mortality 4.9 % vs. 0.3 % among the 610 who did not;
p < 0.0001). Among the1261 patients with MODS on day1, the syndrome worsened in 157 (12.4 %) and remained
unchanged or improved in 1104 (87.6 %) (mortality 22.9 % vs. 6.6 %; p < 0.0001). The AUC of the dPELOD-2 scores
ranged from 0.75 (95 % CI: 0.67-0.83) to 0.89 (95 % CI: 0.86-0.91). The calibration was good with a chi-square test
between 13.5 (p = 0.06) and 0.9 (p = 0.99). The PELOD-2 score on day1 was a significant prognostic factor; the
serial evaluation of the change in the dPELOD-2 score from day1, adjusted for baseline value, demonstrated a
significant odds ratio of death for each of the 7 days.
Conclusion: This study suggests that the progression of the severity of organ dysfunctions can be evaluated by
measuring the dPELOD-2 score during a set of 7 days in PICU, providing useful information on outcome in critically
ill children. Its external validation would be useful.
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Introduction
In the intensive care unit (ICU), almost all adult and
pediatric patients present some organ dysfunction [1–5]
and mortality rates increase with the number of organ
dysfunctions [5–8]. Organ dysfunction scores were
developed in critically ill adults and children to describe
and quantify the severity of organ dysfunctions through-
out the ICU stay. These scores are frequently used as an
outcome variable in clinical trials [9–11]. In 2003 we
developed and validated a multiple organ dysfunction
syndrome (MODS) score for critically ill children: the
pediatric logistic organ dysfunction (PELOD) score using
the most abnormal value of each variable during the en-
tire pediatric ICU (PICU) stay [12]. In 2010, considering
that measurements repeated daily may provide more
useful information, we identified a set of 7 days as the
optimal period for measurement of the daily PELOD
score [13]. In 2013, using a larger and more recent data-
base, we developed and validated the PELOD-2 score,
which, contrary to the first version, uses a continuous
scale [14]. The objective of this study was to validate the
daily PELOD-2 (dPELOD-2) score using the set of 7
days proposed with the previous version of the PELOD
score [13].
Materials and methods
All consecutive patients admitted between June 2006 and
October 2007, to nine multidisciplinary, tertiary-care
PICUs of university-affiliated hospitals (eight French and
oneBelgian, all member of the Groupe Francophone de
Réanimation et Urgences Pédiatriques-GFRUP) were pro-
spectively included. Exclusion criteria were: age 18 years
or older; premature at entry into PICU; pregnancy; total
length of stay in PICU less than 4 h; admission in a state
of continuous cardiopulmonary resuscitation without
achieving stable vital signs for at least 2 h; transfer from
another PICU; and admissions for scheduled procedures
normally performed in other hospital locations. The study
and its database were declared safe and were approved by
the French authorities (Commission Nationale de l’Infor-
matique et des Libertés) on 7 February 2007. The study
design was approved by the ethics committee of the
Société de Réanimation de Langue Française on 27 April
2007 for all the participating hospitals. The requirement
for consent was waived because the study was strictly
observational.
We collected baseline characteristics and calculated
dPELOD-2 score at days 1, 2, 5, 8, 12, 16 and 18 in
PICU. The PICU day 1 started from admission time to
H24, and so on. Length of PICU stay was defined as the
difference between admission day and discharge day plus
1. For each variable, the most abnormal value each day
was used in calculating the dPELOD-2 score [12, 14].
Variables were measured only if requested by the
attending physician (i.e., if justified by clinical status of
patient). Every day, if a variable was not measured, we
assumed that it was identical to the previous measure-
ment (i.e., the physician considered that the value of the
variable did not change) or normal (i.e., the physician
considered that the value of the variable was normal)
[12, 14]. Organ dysfunction was defined as a PELOD-2
score >0 for a given organ, and MODS as the simultan-
eous presence of two or more organ dysfunctions The
PICU discharge status (death/survival) was used as the
outcome dependent variable.
Statistical analysis
All statistical analyses were performed with SAS soft-
ware (SAS institute Inc., Cary, NC, USA). A p value
<0.05 was considered statistically significant. Results are
expressed as frequencies and percentages for categorical
variables and as median and interquartile range (IQR)
for quantitative variables. The comparisons between the
two groups of outcomes and the quantitative variables
were performed using the Wilcoxon signed rank test.
The relationships between the outcome and the categor-
ical variables were analyzed using the chi-square test or
Fischer’s exact probability test.
The discriminant power of the dPELOD-2 scores was
estimated using the area under the receiver-operating
characteristics curve (AUC) (with 95 % confidence inter-
val) and the calibration was assessed using the Hosmer-
Lemeshow chi-square test. We used logistic regression
to investigate the relationship (1) between the dPELOD-
2 scores and outcome, and (2) between the change in
PELOD-2 score from day 1 and outcome.
Results
The study included 3,669 patients, two patients of the
original database [14] with incomplete data being ex-
cluded. Characteristics of the population are reported in
Table 1. The mortality rate was 6.1 % (222 deaths).
Administrative median length of stay in PICU was 3 days
[2–6] in survivors and 4 days [2–12] in non survivors
(p = 0.055).
Daily PELOD-2 score was measured on 7,983 days
(Fig. 1). MODS was present on day 1 in 2,024 of the pa-
tients in the whole population (55.2 %). The dPELOD-2
score was available at least at day 2 in 2,057 patients
(Fig. 1) allowing the identification of new and progres-
sive MODS: among the 796 patients without MODS
(one or no organ dysfunction) on day 1, 186 (23.3 %) ac-
quired the syndrome during their PICU stay (new
MODS); the mortality rate was 4.9 % among these chil-
dren, as compared with 0.3 % among the 610 who did
not acquire the syndrome during their stay (p <0.0001).
Among the 1,261 patients with MODS on day 1, the syn-
drome worsened during PICU stay in 157 (12.4 %)
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(progressive MODS) and remained unchanged or im-
proved in 1,104 (87.6 %); the mortality rate was 22.9 %
among those in whom it worsened and 6.6 % among the
other children; p <0.0001). New or progressive MODS
was reported in 343 patients (9.3 % of the whole
population).
The PELOD-2 score on day 1 was a significant prog-
nostic factor; the serial evaluation of the change in the
dPELOD-2 score from day 1, adjusted for baseline value,
demonstrated a significant odds ratio of death for each of
the 7 days (Table 2). Median (IQR) values of dPELOD-2
scores in survivors and non-survivors are given in Table 3.
The median maximum PELOD-2 score was 5 (2–7) and
differed between survivors and non-survivors (5 (2–7) and
15 (10–20), p <0.0001). The AUC of the dPELOD-2 scores
Table 1 Population characteristics
Variable Value
Total number of patients 3,669
Baseline characteristics
Gender, male, n (%) 2096 (57.1)
Age, months, median (IQR) 15.5 (2.2; 70.7)
0 to <1 months, n (%) 627 (17.1)
1 to 11 months, n (%) 1067 (29.1)
12 to 23 months, n (%) 398 (10.9)
24 to 59 months, n (%) 559 (15.2)
60 to 143 months, n (%) 562 (15.3)
≥144 months, n (%) 456 (12.4)
Recovery post procedure, n (%)a 955 (26.0)
PIM2 score, predicted death rate in %, median (IQR) 1.43 (0.78; 4.33)












Cause of primary diseases at entry, n (%)
Infection 862 (23.5)
Trauma 324 (8.8)
Congenital disease 1123 (30.6)
Drug poisoning 72 (2.0)
Cancer 120 (3.3)
Diabetes 41 (1.1)
Allergic/immunologic diseases 55 (1.5)
Miscellaneous/undetermined 1072 (29.2)
Elective PICU admission, n (%)a 970 (26.4)
Outcomes
Mechanical ventilation, n (%) 1926 (52.5)
Length of ICU stay, days, median (IQR) 3 (2; 6)
Mortality, n (%) 222 (6.1)
aAccording to pediatric index of mortality (PIM2) instructions. IQR interquartile
range, PICU pediatric intensive care unit
Fig. 1 Selection of critically ill children for daily pediatric logistic
organ dysfunction (PELOD-2) score measurements
Table 2 Serial evaluation of the change in the daily PELOD-2
score from day 1, adjusted for baseline value (PELOD-2 score
on day 1)
Variable Odds ratio 95 % CI P value
PELOD-2 score on day 1 1.51 1.44, 1.57 <.0001
Change in PELOD-2 score
Day 1 to day 2 1.30 1.21, 1.41 <.0001
Day 1 to day 5 1.36 1.25, 1.48 <.0001
Day 1 to day 8 1.37 1.23, 1.53 <.0001
Day 1 to day 12 1.30 1.14, 1.49 <.0001
Day 1 to day 16 1.45 1.23, 1.71 <.0001
Day 1 to day 18 1.44 1.21, 1.72 <.0001
Odds ratio (OR) for death are given with 95 % CI. The cumulative OR of death
was calculated as follows: (OR of pediatric logistic organ dysfunction (PELOD)
score on day1) × (OR for change in score from day1 to specified day). For
example, for a child whose score is 10 on day1 and 5 on day12, the change in
score is −5; the OR for death would be 16.60 = ((1.5110) × (1.3−5)). For a child
whose score is 4 on day 1 and 10 on day 8, the change in score is 6; in this
instance, the OR for death would be 34.37 = ((1.514 × 1,376))
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at days 1, 2, 5, 8, 12, 16 and 18 in PICU, ranged from 0.75
(95 % CI 0.67, 0.83) to 0.89 (95 % CI 0.86, 0.91) indicating
moderate to good discrimination (Table 3). The calibra-
tion assessed by the Hosmer-Lemeshow chi-square test
ranged from a chi squared statistic of 13.5 (p = 0.06)
to 0.9 (p = 0.99), indicating good calibration (Table 3).
For each of the 7 days under evaluation, mortality
significantly increased with the number of organ dys-
functions (Table 4).
Discussion
In this study, we report that the dPELOD-2 scores calcu-
lated on the 7 days previously identified, had good dis-
crimination and calibration. This study confirms that the
progression of the severity of organ dysfunctions can be
evaluated by measuring the dPELOD-2 scores during a
specified set of days in PICU (admission and days 2, 5,
8, 12, 16 and 18). Our data not only showed that the
PELOD-2 score on day 1 was a significant prognostic
factor, but also that mortality was significantly higher in
children in whom MODS worsened after day 1 as com-
pared with those in whom MODS remained unchanged
or improved. Thus, it makes sense to collect data daily
on the severity of MODS in order to take into account
this time factor [15, 16]. It has been suggested that
MODS scores are effective in quantifying the severity of
each organ failure during the first ICU days, in adults
[17–19] as well as in children [20]. Furthermore, there is
increasing evidence that the duration and progression of
MODS influence outcome, indicating that MODS is a
dynamic process [15, 20–28].
One can question if it is useful to monitor dPELOD-2
scores during a predetermined set days. Many studies
have demonstrated that daily organ dysfunction moni-
toring can be a useful measurement to estimate the re-
sponse to therapy in a group of patients [29–32]. The
model that we proposed in this study, which includes 7
days distributed over the PICU stay, may represent the
best balance between the workload of assessing daily
scores and the optimal association with prognosis
throughout the PICU stay. There have indeed been a
number of studies in critically ill adults that support
such an approach [18, 21, 33]. Moreover, in studies of
long-stay ICU patients, severity scores at admission fail
to predict mortality [18, 34]. The late events cannot be
predicted with admission or first-day predictive scores,
and this suggest that for patients with prolonged ICU
stay, the calculation of scores on later days, for example
on days 8, 12, 16 and 18, may be useful.
What could be the practical applications of daily
MODS scores? Some pediatric intensivists consider that
an effective assessment of the severity of MODS, like the
PELOD-2 score, is needed to correctly describe the clin-
ical course in critically ill children [10]. The MODS
score can be used as an outcome measure in trials con-
ducted in the ICU [35, 36] and PICU [11, 30, 37, 38]. A
recent study reported that delayed or inappropriate anti-
microbial administration beyond 3 h from recognition of
sepsis is an independent risk factor for prolonged organ
failure and mortality [38]. Our study showed that the
progression of the dPELOD-2 score added information
to the PELOD-2 score for the whole PICU stay. All these
data support the concept that the PELOD-2 score and
its progression in the PICU can be outcome measures of
interest in quality assessment activities and in clinical
trials. New approaches, such as dynamic Bayesian net-
works, using the sequential organ failure assessment
Table 3 Daily PELOD-2 scores among critically ill children: discrimination and calibration





AUC (CI 95 %)
Calibrationa
chi-square (p value)
1 4 (2–6) 12 (8–18) 0.0001 0.89 (0.86, 0.91) 7.7 (0.47)
2 3 (2–5) 8 (5–15) 0.0001 0.83 (0.78, 0.87) 13.5 (0.06)
5 3 (2–5) 7 (5–10) 0.0001 0.80 (0.75, 0.85) 2.3 (0.89)
8 3 (2–5) 7 (5–9) 0.0001 0.80 (0.73, 0.86) 0.9 (0.99)
12 3 (2–5) 6 (5–8) 0.0001 0.75 (0.67, 0.83) 3.0 (0.80)
16 3 (2–5) 6 (4–8) 0.0001 0.78 (0.69, 0.87) 5.2 (0.51)
18 3 (2–5) 6 (5–8) 0.0001 0.80 (0.72, 0.89) 7.6 (0.27)
aHosmer-Lemeshow goodness-of-fit test. PELOD pediatric logistic organ dysfunction, IQR interquartile range, AUC area under the receiver operating
characteristic curve
Table 4 Daily mortality (in percentage) related to organ
dysfunction number
OD number 0 1 2 3 4 5 P valuea
Day 1 0.7 0.8 3.0 9.6 38.0 70.2 <0.0001
Day 2 1.1 1.7 4.3 10.9 36.1 70.6 <0.0001
Day 5 0.6 3.2 8.2 20.1 28.6 50.0 <0.0001
Day 8 1.1 4.2 10.6 24.1 35.0 0 <0.0001
Day 12 3.7 4.9 15.7 27.6 25.0 0 <0.0001
Day 16 4 6.1 18.7 34.6 57.1 NA <0.0001
Day 18 0 6.9 18.4 38.1 44.4 NA <0.0001
aMann–Whitney test. OD organ dysfunction, NA not applicable
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(SOFA) score, suggest that a sequence of organ dysfunc-
tions can be predicted, which allows physicians to antici-
pate the development of MODS and help them
undertake therapeutic decisions [39].
Strengths of this study include that it was prospect-
ive, and it was conducted in nine PICUs across two
countries. It included a large number of critically ill
children (3,669) and a huge number of days in PICU
(more than 7,900 days). Indeed, we have taken into
account the dynamics of organ dysfunctions through-
out the entire PICU stay.
This study is not without limitations. First, the dataset
was collected 8 years ago and the case mix and mortality
rate may have changed over this time period. Second, it
was conducted in only two European countries (France
and Belgium); our population is different from the US
and UK populations [14]. Last, the number of deaths
was quite low after 7 days in the PICU (there were 54
deaths in 557 patients with a length of stay in the PICU
longer than 7 days), but higher than that in our previous
study (33 deaths in 338 patients) [13]. Therefore, a large
prospective study that is not country-specific would be
useful to evaluate external validity of the PELOD-2
score; it should include more critically ill children with a
long-term PICU stay and consider two groups of patients,
those with a short PICU stay (<7 days) and those with a
long PICU stay (≥7 days), in order to collect a sufficient
number of deaths in each group [40]. Interestingly, a re-
cent Portuguese study including 556 critically ill children
admitted to PICU from January 2011 to December 2012
reported good discrimination (AUC 0.94) and calibration
(after recalibration) of the PELOD-2 score [41].
Conclusion
This study shows that the progression of the severity of
organ dysfunctions can be evaluated by measuring the
dPELOD-2 score during a specified set of 7 days in the
PICU. The serial evaluation of the change in the
dPELOD-2 score from day 1, adjusted for the baseline
value, demonstrated a significant odds ratio of death for
each of the 7 days. The daily PELOD-2 score could be a
helpful tool to stratify critically ill children enrolled in
clinical trials, to describe their clinical course, to esti-
mate therapeutic responses and to describe outcomes. It
could also be used for epidemiologic and administrative
purposes. External validation of the PELOD-2 score
needs additional studies including more patients with a
PICU stay ≥7 days.
Key messages
 Progression of the severity of MODS can be evaluated
by measuring the dPELOD-2 score during a specified
period of 7 days in the PICU
 Daily PELOD-2 scores calculated on these days had
good discrimination and calibration when used to
predict short-term mortality
 In children in the PICU, the PELOD-2 score on day
1 is a significant prognostic factor
 New or progressive MODS during the PICU stay is
associated with an increased risk of mortality
 The serial evaluation of the change in the dPELOD-2
score from day 1, adjusted for baseline value,
demonstrated a significant odds ratio of death
for each day
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